SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing heightened scrutiny as it lingers near multi-year lows, sparking a heated debate between investors viewing current levels as a rare accumulation opportunity and others fearing the project has lost its competitive edge. The community remains deeply divided over whether the network's underlying technological adoption and enterprise partnerships will eventually overcome the downward price trend.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently trending as investors weigh its attractive dividend and discounted valuation against significant headwinds in broadband subscriber growth and rising competition. While some in the community view the stock as a long-term income play bolstered by its profitable media assets, others remain skeptical, pointing to the declining cable business and ongoing concerns over the company's debt load.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing intense investor focus as the market anticipates crucial Phase 3 data readouts for its MDD and GAD programs later this year. The community is actively debating the company's clinical prospects, capital runway, and competitive standing against rivals like Compass Pathways while speculating on the impact of potential regulatory breakthroughs and sector-wide volatility.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors react to a significant surge in trading volume and bullish sentiment surrounding the company's QNX software platform, which is increasingly positioned as a foundational technology for Physical AI and autonomous systems. The community is actively discussing upcoming earnings, potential new design wins, and the long-term growth potential of BlackBerry's software-defined vehicle strategy despite historical skepticism from some market analysts.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Papa John's International is currently in the spotlight following reports of a potential $65-per-share take-private deal involving TriArtisan Capital, a development that has triggered significant volatility and trading halts. While investors are actively debating the legitimacy of these reports and the company's long-term valuation, the community is closely monitoring for official confirmation as they weigh the stock's recent performance against the possibility of a buyout.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors weigh conflicting signals from ongoing governance battles, shareholder lawsuits, and high-stakes speculation regarding a potential major data center tenant. While community sentiment is deeply polarized between those betting on long-term infrastructure value and those wary of the company's lack of confirmed deals, intense trading volume and persistent options activity continue to drive heavy engagement on the ticker.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention as it shows signs of a potential breakout, with the community actively debating its role as a peer-to-peer alternative to Bitcoin's store-of-value focus. While some traders are focused on technical resistance levels and upcoming network upgrades as catalysts for momentum, others remain skeptical, citing long-term underperformance and market volatility.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is experiencing significant community attention as investors weigh the impact of shifting interest rate expectations against a flurry of recent M&A activity and positive clinical trial results within the sector. Discussions are currently centered on identifying potential buyout targets and navigating sector-wide volatility, with many community members focusing on managing risk through careful stock selection and long-term thesis validation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is experiencing significant market volatility driven by a major regulatory shift, as the FDA has reversed its stance to allow the company to proceed with an accelerated approval filing path for its Huntington's disease gene therapy. This development has triggered a surge in bullish sentiment and institutional interest, with community members actively discussing the potential for a broader recovery in the biotech sector as the regulatory environment becomes more favorable.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is trending as investors debate the sustainability of the sector's recent rally, with the community actively discussing potential overbought signals and the necessity of portfolio rotation into defensive assets. Sentiment is split between those viewing recent pullbacks as buying opportunities for high-quality tech infrastructure and those hedging against broader market volatility and structural exhaustion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation PR Newswire NEW HAVEN, Conn., June 1, 2026...

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE...

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control...

Biohaven (NYSE:BHVN) Trading Down 7.7% After Analyst Downgrade

Biohaven (NYSE:BHVN) Stock Price Down 7.7% on Analyst Downgrade...

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why

Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Biohaven (NYSE:BHVN) Price Target Cut to $22.00 by Analysts at Royal Bank Of Canada

Royal Bank Of Canada decreased their price objective on shares of Biohaven from $23.00 to $22.00 and set an "outperform" rating on the stock in a report on Tuesday...

Biohaven (NYSE:BHVN) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Biohaven (NYSE:BHVN - Get Free Report) issued its earnings results on Monday. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.17...

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results PR Newswire NEW HAVEN...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Equity

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.57
Prev Close	$13.62
Open	$13.69
Dividend Yield	0.00%
50-Day Moving Average	$10.28
Beta	1.60
Avg. Volume	2.44M
PE Ratio	-2.39

52-Week High	$18.57
52-Week Low	$7.48
Market Capitalization	$2.04B
EPS (Annual)	-$6.86
Price to Book	15.77
Revenue Per Employee	$0.00

BHVNBiohaven Pharmaceutical Holding Company Ltd

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BHVN News